Hemoglobinopathy Treatment Drugs Market Size is Expected to Reach US$6.4 Billion at a CAGR of 8.4% by 2028

Hemoglobinopathy Treatment Drugs Market

Hemoglobinopathy includes a range of disorders, which occur due to the altered structure of hemoglobin.

SEATTLE, WASHINGTON, USA, Feb. 7, 2022 /EINPresswire.com/ — The Hemoglobinopathy Treatment Drugs Market Report 2022-2028 includes a comprehensive analysis of the current market. The report starts with the basic overview of the Hemoglobinopathy Treatment Drugs industry and then goes into every detail.

The Hemoglobinopathy Treatment Drugs market report contains in-depth information about major manufacturers, opportunities, challenges and industry trends and their impact on the market forecast. Hemoglobinopathy Treatment Drugs also provides company and operations data. This report also provides information about the pricing strategy, brand strategy, target customer, list of distributors/traders offered by the company.

Request a PDF brochure with the latest insights here @ https://www.coherentmarketinsights.com/insight/request-pdf/4059

Hemoglobinopathy Treatment Drugs Market – Impact of the Coronavirus (Covid-19) Pandemic

Blood diseases are one of the leading causes of death worldwide. Therefore, the demand for drugs for the treatment of hemoglobinopathy has increased during the COVID-19 pandemic. Thus, the COVID-19 pandemic has not had a negative impact on the growth of the hemoglobinopathy treatment drugs market. However, the pandemic presents particular challenges and dangers for patients with hemoglobin disorders. Hemoglobin disorders are usually not associated with respiratory disorders. However, complications involving the heart, lungs and immune system can be present in these patients and in a SARS-CoV-2 positive patient, this can trigger very serious complications. Due to lockdowns in many countries around the world, various patients with blood disorders at home cannot receive prescribed medications.

Growing number of product approvals and launches, clinical trials of hemoglobinopathy treatment drugs, and partnerships among key players are the major factors driving the growth of the hemoglobinopathy treatment drugs market during the the forecast period.

The launch of new advanced drugs for the treatment of hemoglobinopathy in the market is again expected to contribute to the growth of the drug for the treatment of hemoglobinopathy market. For example, in November 2019, the United States Food and Drug Administration (FDA) approved crizanlizumab-tmca ADAKVEO, from Novartis, to reduce the frequency of vaso-occlusive attacks (VOCs) in adults and elderly pediatric patients. 16 years and older with sickle cell disease. . The recommended dose is 5 mg/kg intravenously over 30 minutes on weeks 0, 2 and every 4 weeks thereafter. The most common adverse reactions (>10%) in patients receiving crizanlizumab-tmca were nausea, arthralgia, back pain and pyrexia.

Get sample report with latest Covid19 analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4059

The increasing clinical trials for hemoglobinopathy treatment drugs are expected to increase the growth of the hemoglobinopathy treatment drugs market over the forecast period. For example, in March 2019, Cambridge, Massachusetts-based Imara Inc. announced that it had raised US$63 million in Series B funding, led by new investors OrbiMed and Arix Bioscience. The company has raised funds for the development of its lead product candidate, IMR-687, which is currently in a Phase II-a trial in sickle cell disease, and moved it into clinical trials later stage. IMR-687 is a phosphodiesterase-9 inhibitor, acting on the same pathway as hydroxyurea, a generic chemotherapy drug commonly used to treat blood disorders and blood cancers.

Browse 31 Market Data Tables and 27 Figures spread over 158 pages and in-depth TOC on Hemoglobinopathy Treatment Drugs Market by Drug Type (Analgesics, Antibiotics, ACE Inhibitors, Hydroxyurea and others), by disease type (thalassemia, sickle cell disease, and other Hb variant diseases), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) and by region (North America, Latin America, Europe, Asia-Pacific, Middle East and Africa) – Forecast to 2027″

The major market players are strongly focusing on adopting growth strategies such as partnership and collaboration for the development of advanced hemoglobinopathy drugs to gain maximum share of the market. For example, in May 2017, Sangamo Therapeutics, Inc. and Pfizer Inc. announced an exclusive worldwide collaboration and licensing agreement for the development and commercialization of gene therapy programs for hemophilia A, including SB-525 , one of Sangamo’s four lead product candidates. . Under the terms of the collaboration agreement, Sangamo received an upfront payment of US$70 million from Pfizer. Sangamo conducted the Phase 1/2 clinical study of SB-525 and some manufacturing activities. Pfizer was responsible for operational and financial support of Sangamo for subsequent research, development, manufacturing, and marketing of SB-525 and additional products.

Hemoglobinopathy Treatment Drugs Market Highlights:

The hemoglobinopathy treatment drugs market is expected to grow at a CAGR of 8.4% during the forecast period (2020-2027), driven by the growing number of product approvals and launches by key players .

Among the drug types, the hydroxyurea segment is expected to hold a major share of revenue in 2027, owing to the growing demand for hydroxyurea drugs to treat pediatric patients, which in turn would increase the demand for drugs for the treatment of hemoglobinopathy. For example, in August 2018, Medunik USA Inc., a company working to improve the health and quality of life of Americans with rare diseases by making orphan drugs available in the United States, announced that the An orphan drug approved by the US FDA, Siklos (hydroxyurea) is now available in 100 mg tablets to order from pharmacies. Siklos is indicated to reduce the frequency of painful experiences and the need for blood transfusions in pediatric patients, aged two years and older, with sickle cell anemia with recurrent moderate to severe painful experiences.

Major players engaged in hemoglobinopathy treatment drugs market are Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaüs Medical Inc., Baxter International Inc., Merck & Co., Inc., Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals and Acceleron Pharma, Inc.

Buy this full business report with a fixed discount of 2000 USD @ https://www.coherentmarketinsights.com/promo/buynow/4059

𝐓𝐡𝐞 𝐚𝐫𝐞 𝐬𝐭𝐮𝐝𝐲 𝐬𝐭𝐮𝐝𝐲 𝐬𝐭𝐮𝐝𝐲 𝐬𝐭𝐮𝐝𝐲 𝐭𝐡𝐢𝐲 𝐭𝐡𝐢𝐲

· The SWOT analysis focuses on the major global manufacturers to define, assess and analyze the market competition. By type, application, and region, the market is defined, described, and forecast.
Examine the main global and regional market potential and benefits, opportunities and challenges, restraints and risks.
· Determine whether trends and factors are driving or restraining market growth.
· By identifying high growth categories, stakeholders would be able to analyze market potential.
· Conduct strategic study of growth trends and market contribution of each sub-market.
· Expansions, agreements, new product launches and market acquisitions are all examples of competitive developments.
· Create a strategic profile of key players and thoroughly analyze their growth plans.

𝗢𝘁𝗵𝗲𝗿 𝗥𝗲𝗽𝗼𝗿𝘁𝘀

Biliary Atresia Treatment Market
Yellow Fever Treatment Market

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and advisory organization that provides syndicated research reports, custom research reports and advisory services. We’re known for our actionable insights and genuine reports in a variety of fields, including aerospace and defense, agriculture, food and beverage, automotive, chemicals and materials, and virtually any field and an exhaustive list of subdomains under the sun. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insights in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.

Mr Shah
Coherent Market Insights Pvt. ltd.
+1 206-701-6702
write to us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Other

Comments are closed.